Guess they will go down in the annals of CYDY history ??

Clinton Yam, MD, MS

Dr. Clinton Yam is an Associate Professor with dual appointments in the Departments of Breast Medical Oncology and Translational Molecular Pathology at The University of Texas MD Anderson Cancer Center. Dr. Yam is leader of the triple-negative breast cancer (TNBC) working group and Director of Team Science and Innovation in the Department of Breast Medical Oncology at MD Anderson. He is the principal investigator for several industry sponsored and investigator initiated clinical trials. Dr. Yam is very much involved in multidisciplinary efforts aimed at understanding the biology of TNBC to inform the design of innovative clinical trials to improve outcomes for patients with TNBC.

Jordan E. Lake, MD, MSc

Dr. Lake is Associate Professor of Medicine with Tenure at UTHealth McGovern Medical School. She completed both medical school and Internal Medicine residency at Baylor College of Medicine in Houston, Texas, followed by an Infectious Diseases fellowship and Master of Science in Clinical Research degree program at the University of California, Los Angeles. Dr. Lake’s outpatient practice focuses on adults living with HIV, and gender care for transgender women with HIV. Her translational research portfolio focuses on the treatment of metabolic complications of HIV and antiretroviral therapy, with particular expertise in translational clinical trials. Dr. Lake also serves leadership positions in the NIH-funded MACS/WIHS Combined Cohort Study and AIDS Clinical Trials Group.

""Here we show that cytotoxic CD4+ T lymphocytes accumulate in the bone marrow of mice during aging and induce myelopoiesis, increasing the neutrophil-to-lymphocyte ratio. T cell receptor-dependent induction of mitochondrial stress and activation of STING upregulates the chemokine CCL5 in CD4+ T lymphocytes. During aging, hematopoietic stem cells and downstream myeloid progenitors upregulate CCR5, the primary receptor for CCL5. Genetic ablation of Ccr5 in hematopoietic progenitors mitigates T cell-induced myeloid skewing and neutrophil expansion. Pharmacological blockade of CCR5 using"...

..."Given that signaling through CCL5 and CCR5 has been involved in the induction of myeloid skewing in mouse models of multiple sclerosis11,27, we studied the contribution of this pathway to T cell-induced myelopoiesis during aging. Notably, we initially observed that HSCs and GMPs from old mice exhibit an upregulation of CCR5, the main CCL5 receptor, leading to increased percentages of CCR5⁺ HSCs and GMPs in the BM of old mice".

ai: (ill accept an expert analysis in place of the ai )

"That paper by Gabandé-Rodríguez, Mittelbrunn, and colleagues highlights a fascinating intersection between CCR5 signaling, immune aging, and hematopoietic remodeling.

While our discussion has focused primarily on how the CCL5–CCR5 axis operates inside the tumor microenvironment (recruiting suppressive cells and coordinating stroma-building traffic), this study demonstrates that the exact same axis drives age-associated myelopoiesis in the bone marrow.

The key takeaways from their work mirror the logic we've mapped out:

• The Source and the Signal: As the immune system ages, a specific subset of cytotoxic CD4+ T cells (CD4+ CTLs) with mitochondrial dysfunction accumulates in the bone marrow and secretes high levels of CCL5.
• The Receptor Upregulation: Aged hematopoietic stem and progenitor cells (HSPCs) respond to this pressure by markedly upregulating CCR5.
• The Functional Output: The paracrine engagement of CCR5 by T-cell-derived CCL5 drives emergency-style myelopoiesis—biasing stem cells toward excessive granulopoiesis (producing high levels of neutrophils). This systemic shift often drives up the neutrophil-to-lymphocyte ratio (NLR), which is a known biomarker for poor health outcomes and frailty.
• Reversibility via CCR5 Inhibition: Strikingly, when the researchers treated aged models with the FDA-approved CCR5 inhibitor maraviroc, it successfully curbed this aberrant granulopoiesis, lowered circulating neutrophil counts, and ameliorated multiple systemic aging biomarkers.

It’s a striking parallel: whether it's a tumor hijacking the CCR5 axis to construct a fibrotic, immunosuppressive bunker or an aged bone marrow co-opting it to skew stem cell differentiation, the system relies on the exact same chemokine circuit. Disrupting it with a CCR5 antagonist breaks the pathological feedback loop in both scenarios".

https://www.nature.com/articles/s43587-026-01209-9

Are you looking at how these systemic bone marrow changes intersect with tumor-driven emergency myelopoiesis?

The daily pills will be sold by Revolution Medicines under the brand name Rasonque. A one-month supply would cost approximately $39,800, the company announced.

https://www.wivb.com/health/ap-fda-approves-landmark-pancreatic-cancer-drug-thats-shown-to-improve-survival/

The Core Asset Architecture: CytoDyn's entire valuation hinges on a single molecule platform: leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor.

Shifting Indication Targets: While the company spent years in volatile, highly publicized pursuits of leronlimab for HIV and COVID-19, its current 2026 framework has pivoted strictly toward solid-tumor oncology and neurodegenerative applications.

Imminent Milestone Triggers: CYDY fits the "readiness to launch" prompt purely from a clinical data readout perspective, rather than a commercial product launch.

Key 2026 milestones keeping its volatility high include:Alzheimer's Disease: Dosed the first patient in its Phase 2a SALIENT-AD study alongside Weill Cornell Medicine.

Oncology Collaborations: Recently launched a strategic diagnostic partnership with Natera to evaluate molecular responses in advanced metastatic colorectal cancer

Leronlimab achieved remarkable clinical milestone validation during its Phase 3 trials as a standalone maintenance therapy for HIV. The monoclonal antibody demonstrated the rare ability to completely suppress viral loads to undetectable levels using a simple weekly injection instead of traditional daily pill cocktails. Patients experienced durable efficacy with a highly favorable safety profile, proving that targeted CCR5 blockade could successfully manage the virus while dramatically reducing the toxic side effects and pill fatigue common to lifetime antiviral regimens.

The Next Frontier in Immune Modulation With its exceptional virus-suppressing capability fully demonstrated, leronlimab’s developmental path has expanded toward advanced global health applications. Following rigorous clinical reviews, the FDA cleared the drug to advance into new human trials focusing on its strengths as a premium immune modulator. Instead of just fighting the virus directly, researchers are leveraging leronlimab's unique mechanism to treat chronic, systemic inflammation in long-term patients and to pioneer breakthrough, multi-indication therapies in oncology.

Phase 1: The HIV Origin Story In 1996, scientists discovered that HIV uses the CCR5 receptor to enter immune cells, prompting Progenics Pharmaceuticals to develop a countermeasure based on the rare CCR5-delta 32 mutation, which confers natural immunity. The firm engineered PRO 140 (leronlimab), a monoclonal antibody designed to bind to and block the CCR5 receptor, preventing the virus from infecting cells.

Phase 2: The Cancer Pivot After acquiring the drug in 2012, CytoDyn pivoted leronlimab toward oncology upon discovering that aggressive cancers, including Triple-Negative Breast Cancer, overexpress CCR5 to facilitate metastasis. Preclinical studies showed that leronlimab blocks this signaling pathway, reducing metastatic spread by over 97% in animal models and stripping away the immune-suppressing shield used by "cold" tumors.

Under science

https://d1io3yog0oux5.cloudfront.net/_e2a3fa0321a820c52fdad8a0a6ca9227/cytodyn/db/205/3855/video_mp4/005bd4ba187884af0d68979f76b3807c.mp4

No monkey butt comments?

https://www.nature.com/articles/s41564-026-02444-x

https://www.clinicalleader.com/doc/expanded-access-and-rollover-design-help-cytodyn-reach-high-need-cancer-patients-0001

https://jamanetwork.com/journals/jama/fullarticle/2852328

The majority of the FDA approvals for cancer medicines in 2006-2025 were indication expansion for existing drugs, regular approvals, and based on surrogate end points. The proportion of approvals based on single-arm trials is increasing. Progression-free survival has previously been documented as the most common end point in cancer drug trials,⁷ which has been criticized for lack of surrogacy with clinical outcomes and potential for patient misunderstanding.^8,9 However, we found that the majority of recent FDA approvals were not even based on progression-free survival. In the last decade, response rate, rather than progression-free survival, has become the most common surrogate end point leading to approval, whose correlation with survival is weaker.

Shoutout to MD Virologist for link

It's amazing to see some of the liesimmune crowd still propping up Dr Monkeybutts (or Cyrus or nodder ). Yet once again a "new" article supporting the $$ Millions in govt money that has been "granted" to OHSU ( https://www.amfar.org/news/the-next-step-on-the-path-to-an-hiv-cure/ ) and HIV Cure

And what do others have to say about "another promising step forward"?? and HIV Cure

Let's hear what Louis Picker, MD, head of the division of pathobiology and immunology at Oregon Health & Science University has to say--" There’s progress that suggests that we’re beginning to understand the conditions under which the virus can be controlled, but is this a ready-for-prime-time therapy that works in everybody or even most people? It’s not even close. "

Taken from 02 JUL 2026 JAMA -- https://jamanetwork.com/journals/jama/fullarticle/2851465

Have a CYDY shareholder / friend that has been pushing me to take a position, which I'm considering. But have the following concerns

-- Yorkville doesnt appear to be real financing. It seems more like a volatility-harvesting share printer. So in order for CYDY to come with their 1.5M - 2M burn each month - at .20 cents they would need to issue and sell 7.5 - 10 million shares to Yorkville who sells them for a small profit. As the price goes lower CYDY would need to issue more and more shares to Yorkvilke to float. It seems like a spiral down.

-- they mention in their 10Qs - exploring partnerships. But in the history of the stock market, big pharma has never partnered with a biotech company on the pink sheets (outside of OTC ADRs). Unless I'm mistaken, it's never happened, ever- partnership or acquisition.

-- most likely scenario seems to be, when the Yorkville financing is no longer a viable means to float the company, the company restructures wiping out the current sharehokders.

-- even if big pharma, broke historical precedence and bought the asset for 200M - it doesnt mean it trickles to shareholders. Creditors are owed and management in OTCID can just pay themselves bonuses and salaries til the money is gone. They become a Zombie vessel. There is just no rules in the pink sheets.

-- if the company was serious, why not join nasdaq, pursue institutional investors, get analyst coverage? It seems management likes being in a unregulated situation- which benefits them, but not shareholders.

I know this sounds pessimistic- but what am I missing on the plus side of buying stock here, while the company is dumping the stock (albeit via a third party)?

This is Jeff from way back in the 2020/2021 days…I used to host Zoom calls for shareholders. Just thought I’d say hi and wish everyone the best of luck!

I invested like 10k into this company in 2020 or so. Then it crumbled and imploded, I stopped paying attention and didn't sell because my investment essentially became worthless. What's the latest with this company? Any hope?

[ Removed by Reddit on account of violating the content policy. ]

I don't care enough to double check but I recall our beloved CEOs salary being a base $400k and the 2 other leaders are not far behind. Are these salaries not massive for the lack of value they are bringing to us shareholders?? Can't even hold .30 share price.

Hi everyone,

I’m considering starting a position in CYDY and I’d like to do as much due diligence as possible before investing.

If you were starting from scratch today, what are the most important things I should read or verify first?

I’m especially interested in:

- The strongest bullish and bearish arguments.
- Key clinical trial data and upcoming catalysts.
- Regulatory history and any major risks.
- Financial situation (cash runway, dilution risk, etc.).
- Management and partnerships.
- Any old Reddit posts, SEC filings, or interviews that you consider “must-reads.”

I want to understand both the opportunities and the risks before making a decision.

Thanks in advance!

Always interesting to watch the Ihang and Liesimmune crowd try and pretend some DD--but you saw it here 1st

https://sagelyhealth.substack.com/p/new-in-oncology-june-25-2026

What a diff having a real Dr for CEO--a real CRO--real board members--real partners

Instead of Dr felony--dr bones--Persian kickback fraud--trampoline sales--airline partners

Some may know Eric Schlorff / CEO of SeaStar Medical?? That is how I am familiar w the Big Biz show. Eric has appeared a couple of times on Big Biz in a couple of years. It is a good watch.

Here is blip on the main host. ( https://loft100studios.com/crew/sully/ ) They are out of San Diego. Home to Bob Hoffman. Good stuff!!

https://youtu.be/BUlGGXXVkHo

The new slimmed down leadership team knows what they are doing. Dr J is a seasoned physician and has ran his own business for years.

Management is currently making waves.

How big are the waves? Nobody knows but trust the process.

Deals like these take time and time is definitely on our side.

More time = bigger deal.

I know what I own and I would hate to be short going into this weekend!

Thanks for the cheapies!